Share:
“RNAi Therapeutics Market”
RNAi therapeutics market was valued at US$ 618.79 million in 2019 and is projected to reach US$ 1,209.29 million by 2027; it is expected to grow at a CAGR of 8.8% from 2020 to 2027.
RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes that are responsible for diseases. At present, the awareness about RNAi is increasing due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the RNAi Therapeutics market growth during the forecast period.However, high cost involved in the development of RNAi therapies is likely to restraint the growth of the market during the forecast years.
Chutes & Ladders—Genzyme vet Sherblom joins ReForm amid subcutaneous delivery shift fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update
Common stock of the merged company, Clene Inc., to commence trading on the NASDAQ Capital Market under the ticker symbol “CLNN” on December 31, 2020
Clinical pipeline includes an ongoing Phase 3 study in amyotrophic lateral sclerosis (ALS) and four concurrent Phase 2 studies in ALS, multiple sclerosis and Parkinson’s disease
Proceeds from the transaction totaled approximately $31.9 million, combining funds held in Tottenham’s trust account and a concurrent $22.4 million PIPE financing
SALT LAKE CITY, Dec. 30, 2020 (GLOBE NEWSWIRE) Clene Nanomedicine, Inc. (“Clene”) (NASDAQ: CLNN), a clinical-stage biopharmaceutical company, today announced the closing of a merger with Tottenham Acquisition I Limited (“Tottenham”) and provided a corporate update. Proceeds from this transaction totaled approximately $31.9 million, which included funds held in Tottenham’s trust ac
Share this article
Share this article
ResearchAndMarkets.com s offering.
Antisense & RNAi Therapeutics Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global antisense & RNAi therapeutics market.
Major players in the antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics and Antisense Therapeutics Ltd.
The global antisense & RNAi therapeutics market is expected to decline from $1.14 billion in 2019 to $1.11 billion in 2020 at a compound annual growth rate (CAGR) of -2.89%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in oper
Global Antisense & RNAi Therapeutics Market Report 2020: 2019 Data and Long-term Forecast to 2023, 2025 & 2030 - ResearchAndMarkets com - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.